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Autism spectrum disorders (ASD) are a spectrum of neurodevelopmental conditions characterized by language deficits, social impairments, and repetitive behaviors (Abrahams and Geschwind, [@B1]). Typically the disorder is diagnosed around 2--3 years of age and manifests with a regression in acquired language and behavioral skills. However, there are wide variations in the clinical presentation and disease progression. In addition to variable severity of the core symptomatology, ASD patients also present with a variable mix of co-morbid conditions: epilepsy, gastro-intestinal problems, intellectual disability, anxiety, and depression (Kim and Lord, [@B20]). Mirroring its clinical heterogeneity, ASD is also genetically very heterogeneous (State and Levitt, [@B36]). Based on the results of genome-wide association (GWAS) studies, candidate gene re-sequencing, and exome-sequencing studies, it is currently estimated that hundreds of genetic variants, including common and rare genetic variants, contribute to the disease (Murdoch and State, [@B25]). What are the molecular pathways that mediate the phenotypic expression of this myriad of genetic variants into a recognizable triad of symptoms? Here we review recent studies demonstrating a convergence of ASD genetic changes toward two main biological processes: synaptic function and immune responses, and discuss their functional interplay, with a focus on immune modulation of neuronal synapses (Figure [1](#F1){ref-type="fig"}).

![**Interactions between synaptic function and immune molecules and cells, and possible mechanisms leading to ASD**. Multiple aspects of synaptic function (blue boxes) are regulated by astrocytes, microglia, and immune molecules (yellow boxes). Either immune activation during neuroinflammation or impaired resting state activity of immune cells in the brain could impair synaptic function and lead to ASD.](fnhum-07-00738-g001){#F1}

From Many Genes to Common Biological Processes {#S2}
==============================================

Results from genome-wide studies are beginning to confirm the long-held hypothesis that the wide variety of genetic variants associated with ASD ultimately converge on a core set of molecular pathways (Murdoch and State, [@B25]). It is worth noting that pathway enrichment analyses are inherently limited by our current knowledge of signaling pathways and molecular interactions, and thus the identification of distinct pathways by different studies might partially reflect yet uncharacterized complexity of molecular pathways.

Four recent studies undertook exome-sequencing in several hundreds of parent-child trios in order to identify *de novo* single nucleotide variants (SNVs) and copy number variants (CNVs) associated with the disease (Iossifov et al., [@B19]; Neale et al., [@B26]; O'Roak et al., [@B29]; Sanders et al., [@B33]). The study by O'Roak et al. found that the most disruptive *de novo* mutations converged onto a highly interconnected beta-catenin/chromatin remodeling protein network, which is involved in neuronal differentiation and synaptic formation (Ille and Sommer, [@B18]). Iossifov et al. found an enrichment of *de novo* variants in genes encoding proteins associated with the fragile X syndrome protein, FMRP, suggesting an involvement in synaptic plasticity. The study by Neale et al. demonstrated that genes carrying functional *de novo* variants were functionally related to each other and to synaptic genes previously implicated in ASD. Using a network-based analysis of genetic association data, Talkowski et al. ([@B39]) showed that rare *de novo* CNVs occurring in ASD cases affect primarily genes related to synapse development, axon targeting, and neuron motility. Collectively, these studies highlighted the fact that genes containing pathogenic DNA sequence variants in ASD patients affected primarily genes involved in various aspects of synaptic function.

While genetic association studies identify genetic loci potentially implicated in the disease, they do not assess the functional consequences of the associated variants. On the other hand, transcriptome analyses comparing disease and control groups assess gene function (by quantifying mRNA output), but are liable to environmental variations in gene expression, and functional changes unrelated to the disease. Thus ideally, functional genomic studies should simultaneously assess DNA sequence variation and gene expression, in a disease-relevant tissue. However, the scarce availability of post-mortem brain tissue from ASD cases limits the sample size of such studies below appropriate statistical power. Attempting to address this problem, we performed a genome-wide assessment of gene expression in multiple brain regions (frontal cortex, temporal cortex, and cerebellum) from 19 autism cases and 17 unaffected controls, and integrated these results with previous ASD GWAS data (Wang et al., [@B42]). Using a network-based approach for the analysis of gene expression data we identified two modules of co-expressed genes dysregulated in a large subset of ASD cases (Voineagu et al., [@B41]). One of these modules was downregulated in ASD brain and was enriched for neuronal genes involved in synaptic function. A second module was upregulated in ASD brain and contained primarily genes functioning in immune and inflammatory responses. To integrate the gene expression results with previously published GWAS data, we performed a pathway enrichment analysis of ASD GWAS data using the two co-expression modules as pre-defined "pathways." We found that the neuronal genes downregulated in ASD, but not the immune/inflammatory genes, showed an enrichment for genetic association, as measured by a large ASD GWAS study (Wang et al., [@B42]). These results supported the heritability of synaptic gene dysfunction in ASD and suggested that the upregulation of immune and inflammatory genes is likely environmentally mediated or secondary to the synaptic dysfunction.

Although gene expression analyses of ASD brain are just beginning to emerge, several studies have evaluated gene expression in readily available peripheral tissues (blood and lymphoblast cell lines) from ASD patients (Hu et al., [@B16], [@B17]; Gregg et al., [@B14]; Enstrom et al., [@B12]). A common result of these studies was the demonstration of increased expression of immune and inflammatory genes in ASD. Moreover, a comparison of gene expression studies of peripheral tissues in idiopathic autism and related neurodevelopmental disorders showed a convergence of gene expression abnormalities on genes involved in immune responses (Lintas et al., [@B21]). Interestingly, an analysis of genetic variants nominally associated with ASD found that these variants were enriched in brain expression quantitative trait loci (brain eQTLs), but not lymphoblast eQTLs (Davis et al., [@B8]). Thus gene expression studies collectively support the concept that (a) immune and inflammatory genes are upregulated in ASD, a phenomenon observed both in the brain and in peripheral tissues, and (b) neuronal synaptic genes are downregulated in ASD brains.

The involvement of synaptic dysfunction and immune responses in ASD had been demonstrated by multiple approaches (Betancur et al., [@B3]; Pizzarelli and Cherubini, [@B32]; Wright and Washbourne, [@B43]; Grabrucker, [@B13]; Onore et al., [@B28]; Zoghbi and Bear, [@B44]; Ebert and Greenberg, [@B11]), but it was not until large-scale genomic studies that these biological processes could be regarded as points of convergence of the heterogeneous genetic variants underlying ASD.

Interplay between Brain Immune Processes and Synaptic Function {#S3}
==============================================================

Microglia, the main resident immune cells in the brain, have been long believed to be active only in response to immune insults, and to exist in a "resting state" in the normal brain. However, this view has dramatically changed over the last decade, and it is becoming increasingly clear that immune cells and molecules play an active role in the normal brain function. Microglia are believed to populate the CNS in the non-vascularized embryonic period and to originate from progenitors from the yolk sac. It has also been proposed that a second wave of microglia, originating from blood monocytes, may populate the CNS during the early postnatal period, a period particularly important for neurodevelopment (Davis and Carson, [@B7]). Microglia actively survey the brain parenchyma, constantly extending their processes to survey their microenvironment every few hours (Nimmerjahn et al., [@B27]). Importantly, microglia are required for synaptic pruning during postnatal neurodevelopment (Paolicelli et al., [@B30]). A recent study (Schafer et al., [@B34]) demonstrated that microglial synaptic pruning is developmentally regulated and depends on neuronal activity. This process was shown to be mediated by the complement receptor (CR3) pathway, and inhibiting CR3 signaling led to sustained deficits in synaptic connectivity.

Thus immune cells could affect neuronal synaptic function either as a result of their activation during immune responses, or due to a failure of their non-immune roles in the brain (Figure [1](#F1){ref-type="fig"}). Recent evidence supports the potential involvement of both of these mechanisms in ASD pathogenesis.

Active neuroinflammation has been consistently demonstrated in ASD brains. Prominent activation of microglia (Vargas et al., [@B40]; Morgan et al., [@B24]), as well as increased levels of inflammatory cytokines and chemokines \[interferon-gamma, IL-1β, IL-6, tumor necrosis factor (TNF)-α\] have been documented in post-mortem brain tissue and cerebrospinal fluid from ASD patients (Onore et al., [@B28]). Recently, activated microglia have also been observed by positron emission tomography in ASD subjects in several brain regions (Suzuki et al., [@B38]). While it is not clear what is the cause of microglial activation in ASD brain, the cytokines produced by activated microglia have been demonstrated to affect neuronal synaptic function (Onore et al., [@B28]). TNF-α regulates neuronal cell proliferation and synaptic pruning (Cacci et al., [@B4]), and modulates synaptic scaling (i.e., the adjustment of synaptic strength for all synapses on a neuronal cell in response to prolonged changes in electrical activity) (Stellwagen and Malenka, [@B37]). IL-1β regulates long-term potentiation and alters synaptic plasticity (Schneider et al., [@B35]), while IL-6 has been implicated in behavioral changes associated with maternal immune activation (Patterson, [@B31]). Mounting evidence suggests that maternal immune activation, particularly during the first and second trimester of pregnancy, may be an important environmental factor in ASD (Onore et al., [@B28]). Rodent models of maternal immune activation exhibit ASD-like behavioral changes (Patterson, [@B31]), and the behavioral effects observed in offspring after maternal immune activation appear to be mediated by microglia and IL-6 (Hsiao and Patterson, [@B15]). In some mouse models increased levels of IL-6 have been sufficient to induce behavioral changes (Onore et al., [@B28]). Unlike peripheral macrophages, microglia are long-lived, and thus it has been hypothesized that they could maintain an "immunological memory" of an early immune insult, leading to long-term neuronal deficits (Davis and Carson, [@B7]).

One of the first studies to demonstrate a direct causal relationship between microglial function and a behavioral phenotype, was a mouse model of obsessive-compulsive disorder (Chen et al., [@B6]). *HOXB8* encodes a homeobox transcription factor expressed in the brain exclusively in bone-marrow-derived microglia. *HOXB8*-null mice exhibit excessive pathological grooming behavior similar to the obsessive-compulsive symptoms of trichotillomania. Chen et al. demonstrated that normal bone marrow transplant could rescue the excessive grooming and hair removal phenotype in the *HOXB8* mutant mouse, and that selective disruption of *HOXB8* in the hematopoietic lineage recapitulates pathological grooming. More recently, a role for non-immune functions of microglia has also been demonstrated in Rett syndrome, a pervasive developmental disorder, belonging to the wider group of ASD. Rett syndrome is caused by loss of function of the methyl-CpG binding protein 2 (*MECP2*) and is characterized by an initial period of normal development of about 5 months followed by deceleration of language development, psychomotor retardation, seizures and loss of social engagement skills (Chahrour and Zoghbi, [@B5]). It was initially believed that Rett syndrome is primarily due to loss of *MECP2* function in neurons. However several recent studies clearly demonstrated that *MECP2* loss in glial cells impairs neuronal function and contributes to the Rett syndrome symptomatology. *MECP2* deficiency in astrocytes leads to impaired BDNF regulation, cytokine production, and neuronal dendritic arborization (Maezawa et al., [@B23]). Moreover, *MECP2*-deficient astrocytes are unable to support normal dendritic ramification of wild-type neurons (Ballas et al., [@B2]). Remarkably, astrocyte-specific expression of *MECP2* in a *MECP2*-null mouse restored the normal neuronal dendritic morphology, improved locomotion, anxiety, and respiratory abnormalities (Lioy et al., [@B22]). A recent study by Derecki et al. ([@B10]) demonstrated that not only astrocytes but also microglia contribute to the Rett syndrome phenotype. Using irradiation-mediated immune ablation in *MECP2*-null mice, followed by wild-type bone marrow transplantation, this study demonstrated that the wild-type microglia could arrest disease development. In addition, targeted expression of *MECP2* in myeloid cells ameliorated the phenotype in *MECP2*-null mice. These results implicated microglia as important players in the pathophysiology of Rett syndrome, and suggested a potential therapeutic benefit of bone marrow transplantation in Rett syndrome.

Conclusion and Future Directions {#S4}
================================

Understanding the core biological processes underlying the clinical and genetic heterogeneity of ASD is as yet in incipient stages. Further advances in elucidating the molecular underpinnings of ASD are expected to result from (a) larger cohort sizes of GWAS and exome-sequencing studies, (b) increased availability of archived post-mortem brain tissue for transcriptome studies, and (c) integrative analyses of genomic, transcriptomic, and epigenomic data.

At the same time, understanding the role of immune cells in regulating synaptic function is also a newly developing field. As discussed above, accumulating evidence supports the notion that immune cells play important roles in normal brain function, outside of neuroinflammation. Of particular relevance to ASD is the role of microglia in synaptic pruning during postnatal brain development, a period that coincides with the onset of ASD symptoms. While it has been demonstrated that increased numbers of activated microglia are present in brain parenchyma of ASD patients (Vargas et al., [@B40]; Morgan et al., [@B24]; Suzuki et al., [@B38]), these studies have not captured the early postnatal development window. Future studies, facilitated by early ASD diagnosis, could shed further light on microglial activation occurs during postnatal brain development and on potential changes in the magnitude of this phenomenon across development and adult life in ASD. Notably, abnormal synaptic density, which could result from a deficit of synaptic pruning, is a feature of several ASD animal models \[e.g., increased synaptic density in *Fmr1* KO mice, and decreased synaptic density in Rett syndrome mouse models (Delorme et al., [@B9])\], but it remains to be demonstrated whether it is also a feature of idiopathic ASD in human brain.

Since microglia and astrocytes have been shown to play a role in synaptic formation and maturation, and mutations in neuronal cell adhesion molecules have been associated with ASD, it is also tempting to speculate that ASD neurons might be particularly vulnerable to immune cell dysfunction in the brain.

Given the large amount of data supporting the role of immune responses in ASD and other neuropsychiatric disorders, advances in deciphering the functional interplay between immune cells and neuronal synaptic function will likely provide vital insights into the mechanisms and potential therapy of neurodevelopmental disorders.
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